LC-MS/MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
== Products == Several types of products, including retail bags, carton liners, bin bags, lidding films and flow pack have been developed from MA/MH films and are commercially available. Each product type is uniquely engineered for the specific produce type (and in some cases, the produce variety) to be packaged. This is done through a rigorous process of developing, testing, adjusting and retesting each MA\MH product both in the lab and in commercial trials. This meticulous process is repeated for each combination of produce and packaging type because of the many factors involved in developing a successful MA/MH packaging. These factors are "storage and shipment temperature, product respiration rate and quotient, response to levels of CO2, O2 and humidity, and product weight. Hence, film packaging that is adequate for consumer packages is not always suitable for bulk packaging and vice versa."
=== May === May 15, 2009: France, Austria, Belgium, Romania, Lithuania, Luxembourg, Portugal, Hungary The French Institute of Statistics and Economic Studies announced that French gross domestic product shrank 1.2% in the first quarter of 2009 after falling by 1.5% in the final quarter of 2008. The French economy had avoided narrowly a recession in 2008. The GDP is expected to keep shrinking in 2009. Eurostat also reported at this time that Austria, Belgium, and Romania had all entered recession in the first quarter of 2009, with two consecutive quarters of shrinking GDP, while Lithuania, Luxembourg, and Portugal had already done so in the last quarter of 2008 and Hungary in the quarter before that.
Joyanti Chutia is an Indian physicist who specializes in solid-state physics and plasma physics. She was among the first women who have headed scientific institutions in India when she became the director of the Institute of Advanced Study in Science and Technology in Guwahati, Assam, which is the first major research institution in North East India. She is a fellow of National Academy of Sciences. She is an emeritus scientist at the Department of Science & Technology in the Government of India.
=== Metropolis-coupled MCMC === Metropolis-coupled MCMC algorithm (MC³) has been proposed to solve a practical concern of the Markov chain moving across peaks when the target distribution has multiple local peaks, separated by low valleys, are known to exist in the tree space. This is the case during heuristic tree search under maximum parsimony (MP), maximum likelihood (ML), and minimum evolution (ME) criteria, and the same can be expected for stochastic tree search using MCMC. This problem will result in samples not approximating correctly to the posterior density. The (MC³) improves the mixing of Markov chains in presence of multiple local peaks in the posterior density. It runs multiple (m) chains in parallel, each for n iterations and with different stationary distributions
Sources: en.wikipedia.org
First, it should dissolve the solid compound to be analysed (with or without the aid of a cosolvent or additive), thus allowing molecules of that compound to diffuse to the surface layers, replenishing the sample molecules that have been ionized or destroyed by interaction with the fast atom beam. Another mechanism for explanation of ion formation in FAB involves the idea that sputtering occurs from the bulk rather than the surface, but in that case, the solubility is still largely important to insure homogeneity of solid analyte in the bulk solution. Secondly, the matrix should have a low volatility under the conditions of the mass spectrometer. As mentioned above, as the matrix is depleted, the ionization decreases as well, so maintaining the matrix is vital. Thirdly, the matrix should not react with the solid analyte in question, or if it does react, it should be in an understood and reproducible way. This ensures reproducibility of analysis and identification of the actual analyte rather than a derivative of the analyte. The most commonly used compounds as a matrix are variations of glycerol, such as glycerol, deuteroglycerol, thioglycerol, and aminoglycerol. If the sample cannot dissolve in the chosen matrix, such as glycerol, a cosolvent or additive can be mixed with the matrix to facilitate the dissolving of the solid analyte. For example, chlorophyll A is completely insoluble in glycerol, but by mixing in a small amount of Triton X-100, a derivative of polyethylene glycol, the chlorophyll becomes highly soluble within the matrix.
Ribosomal RNA organizes into two types of major ribosomal subunit: the large subunit (LSU) and the small subunit (SSU). One of each type come together to form a functioning ribosome. The subunits are at times referred to by their size-sedimentation measurements (a number with an "S" suffix). In prokaryotes, the LSU and SSU are called the 50S and 30S subunits, respectively. In eukaryotes, they are a little larger; the LSU and SSU of eukaryotes are termed the 60S and 40S subunits, respectively. In the ribosomes of prokaryotes such as bacteria, the SSU contains a single small rRNA molecule (~1500 nucleotides) while the LSU contains one single small rRNA and a single large rRNA molecule (~3000 nucleotides). These are combined with ~50 ribosomal proteins to form ribosomal subunits. There are three types of rRNA found in prokaryotic ribosomes: 23S and 5S rRNA in the LSU and 16S rRNA in the SSU. In the ribosomes of eukaryotes such as humans, the SSU contains a single small rRNA (~1800 nucleotides) while the LSU contains two small rRNAs and one molecule of large rRNA (~5000 nucleotides). Eukaryotic rRNA has over 70 ribosomal proteins which interact to form larger and more polymorphic ribosomal units in comparison to prokaryotes. There are four types of rRNA in eukaryotes: 3 species in the LSU and 1 in the SSU. Yeast has been the traditional model for observation of eukaryotic rRNA behavior and processes, leading to a deficit in diversification of research.
An evaporative light scattering detector (ELSD) is a destructive chromatography detector, used in conjunction with high-performance liquid chromatography (HPLC), ultra high-performance liquid chromatography (UHPLC), purification liquid chromatography such as flash or preparative chromatography (using a splitter), countercurrent or centrifugal partition chromatography and supercritical fluid chromatography (SFC). It is commonly used for analysis of compounds that do not absorb UV-VIS radiation significantly, such as sugars, antiviral drugs, antibiotics, fatty acids, lipids, oils, phospholipids, polymers, surfactants, terpenoids and triglycerides. ELSDs works by nebulizing the column's effluents into a fine aerosol mist, which then passes through a heated drift tube, where the solvent evaporates. Thus, it can be easily used in gradient method of LC and SFC. The remaining non-volatile analyte particles are carried further by a carrier gas to a light scattering cell, where a beam of light illuminates them and they scatter it. The scattered light proceeds to a photodiode which converts it to a signal, which is proportional to the mass of the analyte particles. This is why it is considered as a sort of "universal detector" as it is able to detect all compound which are less volatile than the mobile phase, i.e. non volatile and semi-volatile compounds. ELSD is related to the charged aerosol detector (CAD), in which the aerosol is charged. Like the CAD, it falls under the category of destructive detectors.
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.